New pill XTYW007 enters human testing for fatty liver
NCT ID NCT07407634
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called XTYW007 in healthy volunteers and people with high LDL cholesterol. The main goal is to check the drug's safety and how the body processes it, not yet to see if it treats non-alcoholic fatty liver disease (NAFLD). The study will involve 94 participants and includes both single and multiple doses, as well as looking at the effect of food on the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XTYW007 capsules
What this could lead to
If this early trial shows XTYW007 is safe and well-tolerated, it could pave the way for larger studies to see if it helps control non-alcoholic fatty liver disease.
What could go wrong
This is a very early (Phase I/IIa) trial with only 94 participants, focused on safety and dosing, not on whether the drug actually works. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Jilin City, Changchun, China